GLP-1 on Non-ST-Segment Elevation Myocardial Infarction
Myocardial Infarction
About this trial
This is an interventional treatment trial for Myocardial Infarction focused on measuring Glucagon-like peptide-1, Non-ST-segment elevation myocardial infarction, Left ventricular ejection fraction
Eligibility Criteria
Inclusion Criteria:
non-ST-segment elevation myocardial infarction (NSTEMI )
Exclusion Criteria:
- unconscious at presentation
- had ST-segment elevation acute myocardial infarction
- NSTEMI requiring emergency percutaneous coronary angiography
- valvular heart disease
- cardiogenic shock
- hypoglycaemia
- diabetic ketoacidosis
- had a history of myocardial infarction
- stent implantation
- renal insufficiency
- had previously undergone coronary artery bypass surgery.
Sites / Locations
- PLA General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Experimental
Placebo Comparator
GLP-1 group
placebo
liraglutide (Novo Nordisk, Bagsværd, Denmark); the frequency: Subcutaneous liraglutide were taken daily; duration: 7 days. After admission, the patients were treated with 0.6 mg liraglutide once daily for 2 day, then 1.2 mg liraglutide for another 2 day, and then 1.8 mg liraglutide for 3 days.
placebo (Novo Nordisk, Bagsværd, Denmark); the frequency: Placebo were taken daily; duration: After admission, the patients were treated with 0.6 mg placebo once daily for 2 day, then 1.2 mg placebo for another 2 day, and then 1.8 mg placebo for 3 days.